United States — Food and Drug Administration & Moderna

United States — Food and Drug Administration: The FDA granted approval for mFLUSIVA, marking a regulatory milestone and demonstrating its role in vaccine oversight despite internal controversies.

Moderna: Moderna received its fourth FDA-approved product and first mRNA flu vaccine, boosting its commercial prospects and validating its mRNA platform.

United States — Food and Drug Administration: The United States — Food and Drug Administration (FDA) is the regulatory body responsible for approving the mFlusiva vaccine. Its advisory committee's unanimous recommendation is a crucial step towards the vaccine's market entry, despite internal disputes and leadership vacancies.

Moderna: Moderna is the developer of the mFlusiva mRNA flu vaccine, which is currently under review for approval by the United States — Food and Drug Administration. The positive recommendation from the advisory panel is a significant step towards market entry, potentially boosting its stock and market position in the vaccine sector.

United States — Food and Drug Administration: The FDA granted approval for the first mRNA flu vaccine, a regulatory milestone that validates the safety and efficacy of mRNA technology for seasonal influenza prevention.

Moderna: Moderna, a key player in mRNA vaccines, is likely to see increased investor confidence and market opportunities following the FDA's approval of an mRNA flu vaccine.

United States — Food and Drug Administration: The United States — Food and Drug Administration is the regulatory body with whom Moderna will discuss the next randomized stage of development for SRD-002, making its involvement crucial for the therapy's future.

Moderna: Moderna is the clinical-stage biotechnology company developing the gene therapy SRD-002 for heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). The positive DMC recommendation for its MUSIC-HFpEF trial and the ongoing MUSIC-HFrEF trial are significant milestones for the company, supporting its continued advancement in cardiovascular gene therapy.

United States — Food and Drug Administration: The FDA will review the trial data for potential approval. The companies plan to file for approval, and the vaccine could be available as soon as 2027 if approved.

Moderna: Moderna is the co-developer of the vaccine and the primary beneficiary, with its stock more than doubling and adding about $40 billion in market value. The trial success validates its mRNA platform and could lead to a new revenue stream, helping the company return to profitability.

United States — Food and Drug Administration: The FDA is the agency being led. It faces staff losses, morale issues, and policy controversies; Overton's nomination could exacerbate these challenges.

Moderna: Moderna, a vaccine maker, had disagreements with the FDA. Overton's vaccine stance may affect future approvals.

United States — Food and Drug Administration: The United States — Food and Drug Administration has approved Inmazeb, a combination of antibodies, to treat Zaire Ebolavirus infection, which Regeneron Pharmaceuticals has donated for potential use in the current outbreak.

Moderna: Moderna is one of the entities developing an experimental vaccine for the Bundibugyo virus, which could lead to future revenue and enhance its reputation in vaccine development.

United States — Food and Drug Administration: Mentioned in context of vaccine authorization; not directly involved in the released texts.

Moderna: One of the vaccine manufacturers; similar to Pfizer, minimal direct impact.

United States — Food and Drug Administration: The FDA approved Palsonify in 2025, enabling its commercial availability. The agency's regulatory decisions are relevant to the value of the acquired assets.

Moderna: Moderna is a partner with Vertex in developing CF treatments for patients not covered by Vertex's CFTR modulators. The acquisition does not directly affect Moderna.